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I 
am humbled to have served as President of SA Heart® 
and I have outlined in detail last year’s activities in 
my 2019 report, which is available online at 
www.saheart.org. I appreciate all the encouragement and 
assistance from Professor Liesl Zühlke and Ms Erika Dau, as 
well as our board of directors, the national council, standing 
committees and regional branches. 
We are presently in the process of re-aligning our 
memorandum of incorporation to make  SA Heart® more 
inclusive. This is a long and arduous process and we are 
fortunate that we have been ably guided Mr Chandu 
Kashiram, who is a self-employed business consultant with 
expertise in risk management, ethics, governance, com-
pliance and fi nancial management. We are grateful that 
Chandu has volunteered his services to our association. 
This process has been a sobering education as I personally 
did not appreciate the actual responsibilities that are 
required as a board director. We intend to not differentiate 
between various categories of membership and henceforth, 
all allied cardiac professionals will be included as ordinary 
members with voting rights and inclusion on the SA Heart® 
board. In addition we will have a number of independent 
directors as well – these will be individuals with added 
value business and fund-raising skills. The composition of 
the board and other important aspects are still under 
discussion and we will hold a special meeting for the 
membership to accredit this important document. 
Other highlights for me personally include a major role in 
the organisation (together with the Durban Scientifi c 
Committee) of our recent successful PASCAR, SA Heart®, 
Africa PCR, SA-CMR and AHN congress. The coming 
together of 5 major groups was momentous in that we 
were able to strengthen collaborations and explore 
solutions for the epidemic of heart disease in Africa.  We 
also held a well-attended SA Heart® - ESC joint  symposium, 
“Infection, infl ammation and the heart” at the recent 
ESC 2019 congress in Paris. I was honoured to represent 
SA Heart® at the Affi liated Cardiac Societies Presidents 
meeting, in addition to a meeting with the ESC leadership. 
We have now committed to provide our local perspectives 
for publication together with the future planned ESC 
Practice Guidelines,  that we adopt as own. The ESC would 
like to better cater their recommendations for developing 
countries. 
We are now in the planning phase of for this year’s 
congress, “2020: Back to the Basics”. We want to get back 
to the fundamental basis of cardiovascular disease and 
cardiac practice. We welcome our long-term partnership 
with AfricaPCR. We will closely coordinate and integrate 
both committees. A needs analysis has been sent to the 
entire membership for suggestions of sessions in line with 
this theme. 
Once again I welcome any constructive input that you may 
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he annual SA Heart® congress took place from 
Thursday 31 October - Sunday 3 November 2019 
at the Sandton Conference Centre. The congress 
theme for last year is “Cardiac Care: Meeting the needs of 
Africa”. This is a highly pertinent issue in a world where, 
according to the 2013 Global Burden of Disease Study, 
cardiovascular disease (CVD) has been identifi ed as the 
leading cause of death worldwide. It is predicted that CVD 
will surpass HIV/AIDS as the leading cause of death in sub-
Saharan Africa (SSA) within the next decade. 
The congress theme and topics were thus selected to 
facilitate a focus on where? and how? modern cardiac care 
can be most effectively utilised in an under-resourced 
environment. When comparing this conference to previous 
years, regular attendees will have noted a few changes to 
the form and content. Last year, 5 major cardiac societies 
have joined forces to highlight problems and explore 
possible solutions to the challenges inherent to treating 
heart disease in Africa with SA Heart® partnering with the 
Pan-African Society of Cardiology (PASCAR), AfricaPCR, 
the Cardiovascular Magnetic Resonance Congress of 
South Africa (SA-CMR) and the African Heart Network 
(AHN). It was wholly appropriate for SA Heart® 2019 to 
be held in association with AfricaPCR. The case based, 
interventional programme and joint sessions, as organised 
by the 2 bodies, was tailored to focus on areas of conten-
tion as well as modern trends in cardiology and their 
importance for, and relevance to, the practice of cardiology 
in Africa.
PASCAR focused on identifying key issues to help guide 
the implementation of treatments and programmes to 
combat CVD on the African continent. SA-CMR brought a 
unique imaging dimension to the conference with a timely 
focus on myocardial and pericardial diseases which are all 
too prevalent in Africa. The AHN focussed on advocacy 
and policy in an effort to specifi cally identify and address 
unmet needs. This is crucially important if we are to meet 
the stated aim of the World Health Organisation (WHO) 
to reduce CVD with 25% by 2025.
The preconference workshops took place on Thursday 31 
October and included a stimulating paediatric programme, 
a practical echocardiographic session, the ever popular 
“Cardiology for non-cardiologists” under the aegis of 
HefSSA as well as workshops presented by SA-CMR and 
CASSA. Every one of these sessions focused on the 
acquisition of certain skills which are necessary to improve 
one’s cardiology practice. These workshops were followed 
by the opening plenary on Thursday evening. The PASCAR 
tradition that participants wear traditional dress for this 
function was upheld.
In light of the conference theme, which can be paraphrased 
as “How to make a difference”, there could scarcely be a 
more appropriate keynote speaker than Dr Imtiaz Sooliman 
of Gift of the Givers.
The fi rst morning saw the conference proper presenting a 
major plenary, put together by AfricaPCR and SA Heart®, 
with topics such as appropriate management of STEMI, 
revascularisation in chronic coronary syndromes and TAVI. 
On the second morning, the initial major plenary session 
named the Bongani Mayosi Memorial Lecture, saw many of 
Bongani’s friends and associates will pay tribute to one of 
Africa’s greatest medical sons. The focus was on rheumatic 
SA HEART® CONGRESS REPORT 2019
Dr Rob Dyer
105
heart disease with 2 talks specifi cally emphasising mitral 
valve disease.
We are grateful for the ESC’s support and their willingness 
to contribute to the success of our conference. The second 
major plenary session on Friday and Saturday included an 
ESC session focusing on guidelines and modern trends. The 
format adopted included multimedia and case-based 
discussions covering atrial fi brillation, chronic coronary 
syndromes, pulmonary thromboembolic disease, the 
diabetic cardiac patient, lipid therapy and heart failure. In 
addition to the substantial contribution from the ESC, we 
welcomed input from our Mayo Clinic colleagues who 
have made particular contributions to the imaging sessions 
and who have also shared their insights and experience on 
a vast range of topics.
The late Friday afternoon major plenary session included a 
debate on AF-ablation vs. medical therapy, a presentation 
on CT angiography, major insights on all forms of manage-
ment of chronic coronary syndromes from 2 of the world’s 
experts (Drs Gersh and Wijns) and a bonus presentation 
on the future of randomised trials presented by Dr Rory 
Collins.
The fi nal Sunday morning plenary was markedly interactive 
and loads of fun. It was divided into 2 sections: “What 
could go wrong?” and “Where technology made a 
difference”. Other major areas which addressed in the 
special interest sessions were Athlete’s heart, paediatric 
cardiology (medical and surgical), arrhythmias, hypertension 
and GUCH.
The tremendous cooperation of all in putting together the 
programme is hereby gratefully acknowledged.
Dr Rob Dyer
Elizebeth Schaafma and her award for the 
best poster.
Professor Barbara Cassedei at a career cafe session.
CVD has 
been identifi ed 
as the leading 





After nominations and elections in September/October last year, new offi cer bearers of the current SA Heart® executive were 
announced at the SA Heart® AGM.
Dr Blanche Cupido – President-Elect  I  Professor Mpiko Ntsekhe – Vice President  I  Dr Zongezile Makrexeni – Secretary
Congratulations to these members and best wishes for a successful term.
POPULAR CONGRESSES FOR 2020
 CONGRESS DATE CITY COUNTRY
Please also consult the SA Heart® online calendar at www.saheart.org/events/eventcalendar for constant updates as well as a 
number of ISCAP workshops and SASCI/SA Visiting Professor evening lectures around the country.
Please double check all dates and events as they might change under these unprecedented circumstances.
EUROPCR 18 - 21 May 2020 Paris France
https://www.pcronline.com/Courses/EuroPCR
CCSSA (CRITIAL CARE SOCIETY OF 26 - 29 August 2020 Johannesburg South Africa
SOUTHERN AFRICA) CONGRESS 
Email ccssacongress@velocityvision.co.za
ESC CONGRESS 2020 29 August - 02 September 2020 Amsterdam Netherlands
https://www.escardio.org/Congresses-&-Events/ESC-Congress
2020 WORLD HEART AND CARDIOTHORACIC 08 - 09 September 2020 Bangkok Thailand
SURGERY CONFERENCE 
https://heart.episirus.org
CSI FRANKFURT 16 - 19 September 2020 Frankfurt Germany
https://www.csi-congress.org
LIPIDOLOGY UPDATE MEETING 18 - 21 October 2020 TBC South Africa 
Email elouise@shiftideas.co.za




11TH ANNUAL CONFERENCE, JOHANNESBURG 2019
The aim of this course, as quoted from their website, was to provide physicians and sonographers with the opportunity to 
improve their knowledge in echocardiography. A second aim was to provide practical training to participants on various 
echocardiographic techniques. Since its beginning in 2009 this course has grown in popularity and in 2013 was given offi cial 
endorsement from the European Cardiovascular Imaging Society. The current course is aimed at providing attendees with 
updates on echocardiographic practice guidelines as well as a comprehensive introduction on three dimensional 
echocardiography. 
Ensuring a high level of quality in echocardiography and new advances in technology, a comprehensive team of world experts 
has joined this programme since its inception (B Khandheria, P Nihoyannopoulos, F Mookadam, J Bax, F Peters) to provide 
state of the art teaching and formulating exciting topics which this year was mostly cased based learning and a few hands-on 
sessions.
The 4-day programme was of great value to me as a fi rst year senior registrar in cardiology at Groote Schuur hospital, almost 
all topics discussed had high relevance to my current curriculum and daily clinical practice. These included myocardial disease, 
the cancer patient, the challenge of endocarditis, aortic valve disease, case studies in mitral valve disease, pericardial disease 
pearls and ICU challenges.
Recording all the sessions on the livemedia.com web site for easy access and review was an excellent addition to the new 
horizons programme to enable maximum benefi t for all attendees.
I hope the 12th annual conference continues to bring the best and add to the previous success. 
Mahmoud Al-Naili
NEW HORIZONS IN ECHOCARDIOGRAPHY
Dr Mahmoud Al Naili, Professor F Mookadam, 
Professor P Nihoyannopoulos, Professor J Bax and 




n the 1st November 2019, the Sandton Sun was 
awash with red! Not only was it declared “Go 
red for women” day at SA Heart® congress, it 
also marked the launch of the “Women as One” African 
Chapter. Women as One was launched by 2 remarkable 
women cardiology icons: Professor Marie-Claude Morice 
and Professor Roxana Mehran together representing 2 of 
the biggest names in Interventional cardiology and CVD 
clinical trials in the current day.
Women As One aims to broaden and promote the global 
talent pool in medicine by providing unique professional 
opportunities to women physicians. Their objectives are to: 
 ■ Unify professional organisations in specialties where 
women are underrepresented, creating a single infra-
structure to support change.
 ■ Develop innovative and compelling programmes which 
serve to advance women in medicine.
 ■ Leverage lessons from other industries, incorporating 
“what works.” 
 ■ Match the right women to the right opportunities!
Professor Liesl Zühlke had been invited to their fi rst 
European Meeting in April 2019 and recognised, as one of 
the few women cardiologists in senior positions in South 
Africa, that there was a clear need for engaging around 
this issue. Taking advantage of the visit by Professor Mari-
Claude Morice for SA Heart® 2019 and AfricaPCR, the 
WOMEN AS ONE EVENT AT SA HEART® CONGRESS
Professor Liesl Zühlke, Dr Blanche Cupido and 
Professor Karen Sliwa at the Women as One event.
TEAM COMPOSITION: SENIORS AND JUNIORS
SENIORS JUNIORS
Vast minority women (0% - 20%)
Minority women (21% - 49%)
About an equal ratio of women 
to men (50% - 59%)
Majority women (60% - 79%)
Vast majority women (80% - 100%)
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decision was made to launch an African Chapter of 
Women as One, to ensure high visibility by all dressing 
in red and to present the fi ndings of a short survey over 
lunch.
We were very happy to have over 50 respondents to our 
survey and had arranged for a lunchtime meeting room 
which could seat about 60 people. Imagine the surprise and 
delight when the sea of wonderfully red dressed women 
(and men) descended on the room, which was clearly far 
too small. There was a rapid relocation to a far larger room 
and in the end over 150 people joined the lunch. The 
program began with an introduction to the Women as 
One concept by Liesl Zühlke, followed by wonderful short 
talks by Professor Karen Sliwa and Professor Barbara 
Caseidi, the fi rst women to lead global cardiology agencies. 
Also part of the audience, was Professor Athina Poppas, 
The Women as one Attendees looking lovely 
in Red.
the fi rst women president of ACC. Karen discussed The 
World Heart Federation: Increasing women on the global 
stage of cardiology while Barbara Casadei talked about 
Women in the ESC: Challenges and opportunities. The 
fi nal session consisted of 3 questions answered by both the 
panel and then the audience. The panel consisted of 
Professor Amam Mbakwem, Professor Ana-Olga Mocumbi, 
Dr Blanche Cupido and the topic was Accelerating capacity 
and talent in cardiovascular sciences and practice in Africa.
The fi rst questions was posed to Dr Ana-Olga Mocumbi 
and addressed the biggest challenge facing her in her 
career. Many of those she encountered were shared by 
both the men and the women who had answered the 
survey – we are not so different!  A clear concern was the 
lack of female mentors, institutional culture and othering. 
Professor Amam Mbakwem addressed the issue of 
facilitators and spoke about vision, drive and determination, 
and the cooperation and collaboration between colleagues 
and friends. Finally Dr Blanche Cupido, SA Heart®’s new 
president elect who will become the third woman 
President of SA Heart® in the past 4 terms, spoke about 
potential interventions to accelerate potential amongst 
woman cardiologists and trainees. She addressed the 
issue of informal and formal support and mentorship, a 
focus on new areas of expertise and the importance of 
BOX 1 CHALLENGES BOX 2 FACILITATORS
BOX 3 SUGGESTED 
INTERVENTIONS
• Family and work fl ow, fl exible hours
• Patriarchy
• Funding- both for research and for 
further qualifi cations/studies
• Toxic Institutional culture 
• Poor support
• Burden of Disease
• Lack of qualifi cations available
• Long hours
• Equipment and capacity building
• Lack of senior posts
• Lack of mentors
• Non-invasive cardiology viewed 
differently to Interventional cardiology
• Age
• Strong (female) mentorship, 
who care
• Support from family
• Having a strong vision
• Awareness of NCD and CVD 
as an issue
• Collaboration
• Skill set and experience
• (Having and being) Younger 
committed trainees
• My Age
• Female networking societies
• More understanding from 
male colleagues, with regards to 
one’s family responsibilities
• Broad Diversity and inclusivity
• Active and visionary women leaders
• Funding and education about 
what it entails
• Female Mentors
• Career awareness, certifi cation, 
educational opportunities
• Ringfenced opportunities
• More women in senior positions
• Focus on the girl child
• Flexible working structures and hours
Continued on page 110
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visibility and commitment, even in the face of diffi culty and 
obstacles as a method of ensuring suffi cient rungs on the 
ladder while looking toward to the glass ceiling.
Women as one refl ects the new ethos of SA Heart®: 
potential for all who practice Cardiology in Africa, regard-
less of origin, discipline and certainly not gender! We now 
have a diversity policy in all our committees and within the 
organisation and a focus on respectful engagement. All the 
large agencies including ESC, WHF and NIH have pledged 
to no longer have man-only panels, all new committees 
have been instructed to ensure that all speaker profi les 
are diverse and include emerging leaders, women and 
practitioners from diverse areas and backgrounds. 
SA Heart® applauds these initiatives and will continue to 
refl ect these in our work and congress going forth.
The Women as One day ended with lots of photographs 
and fun together and a real sense of purpose and com-
Jaco Joubert is currently the 
Country Manager for Edwards 
Lifesciences. He’s been in the 
cardiac device industry since 
2004 and has had the privilege 
to serve in various roles in 
the sales and marketing arenas 
for various international com-
panies.
Jaco qualifi ed as a pharmacist and spent the fi rst 6 years as 
a retail pharmacist. He completed a Marketing Diploma 
from the IMM Institute of Marketing in 2005. 
His passion is problem solving and he believes that any 
problem has a solution if you are willing to explore a few 
options and don’t accept failure. He’s an eternal optimist 
and believes that with a positive outlook you can overcome 
any challenge you may face. 
Norah Maitisa is currently a 
Medical Advisor at MSD South 
Africa for Lipids, Hypertension, 
Diabetes and Pain portfolios. 
She has also previously worked 
at GSK’s Respiratory and HIV 
portfolios. She has worked 
in several NGO’s contributing 
towards government’s primary 
health care nurse management of HIV&TB and has con-
tributed towards the PC101 (TB&HIV) formulation within 
its working groups. After qualifying from MEDUNSA, she 
also acquired her Master in Science Infectious Disease 
Epidemiology (MSc Epidemiology) from Wits university.
Norah Maitisa and Jaco Joubert have been nominated as 
the new pharma and device industry representatives by 
SAMED after Rob Millar resigned from his position in 
industry in 2019. 
mitment. The Women as One escalator award was 
announced and all in the audience were encouraged to 
apply. We intend to follow this event in 2020 with a CVD 
Imbizo within the conference dedicated to Empowering 
and Escalating women with key learning objectives and 
powerful interactions and networking.
Please go onto the women as one website 
https://www.womenasone.org 
to register onto the talent directory, 
https://www.womenasone.org/register 
browse the amazing resources 
https://www.womenasone.org/videos and 
view more pictures from this 
wonderful event.
Liesl Zühlke
WOMEN AS ONE EVENT AT SA HEART® CONGRESS continued




his newsletter provides a report of the FH 
Foundation Global Summit meeting to which I was 
invited. The meeting was in Atlanta, Georgia, USA 
from Sunday 20 - Tuesday 22 October. It was attended by 
medical and scientifi c colleagues as well as patients. The 
content of the meeting is summarised and some of my 
refl ections are added with the South African perspective. 
The report is not comprehensive but is hopefully informa-
tive. There is much to do to promote the awareness of 
familial hypercholesterolaemia (FH).
In brief, the FH Foundation, a patient-driven organisation, 
was founded by an enthusiastic woman who had an heart 
attack before the age of 40 years due to familial hyper-
cholesterolaemia (FH). There has been an annual meeting 
since 2012. The FHF invites clinicians and scientists to give 
input into their activities so that the recognition and 
treatment of FH can be promoted. Last year it celebrated 
the 20 years since the special report from the World 
Health Organisation which I attended as one of the few 
remaining co-authors on that report. Following the global 
summit last year I have, on behalf of LASSA, contributed to 
a document on FH which will be submitted for publication 
later this year.
The theme of this meeting was Familial Hypercholes-
terolaemia as a model for Precision Public Health. At the 
opening of the meeting, the founder and now chief exe-
cutive offi cer of the FHF, Ms Katherine Wilemon explained 
that the theme of precision public health was in response 
to the coining of the term by Dr M Khoury in 2016 as part 
of the development of precision medicine. The aim is to 
provide the right intervention(s) at the right time to the 
right population or sector thereof. She indicated that, in the 
USA the number of persons with FH exceeds the number 
of HIV-infected persons by more than 200 000. Since the 
introduction of an ICD-10 code specifi cally for the diag-
nosis of FH, it has been possible to track this diagnosis 
better. The ICD 10 code for FH is E78.01.
Dr J Knowles summarised progress since the FHF got 
involved in highlighting the plight of FH sufferers. Not only 
has the FHF provided a home for patients to turn to for 
THE LIPID AND ATHEROSCLEROSIS SOCIETY OF 
SOUTHERN AFRICA (LASSA) 
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information and support, but it also raised funds to support 
its advocacy for persons with FH. He indicated that much 
education still needs to be done as the awareness, assessed 
by a survey in general practitioners, cardiologists, other 
specialists and paediatricians was not ideal: 15, 61, 45 and 
5% from each of the groups felt they knew the condition 
and answered appropriately. A registry of FH was started 
and was 6 000 strong; amongst them are 88 homozygous 
cases of FH. The average age of starting treatment for 
these subjects is 44 years and of diagnosis is 48 years. The 
genetic diagnosis was made in 10% of cases and comprises 
LDL receptor mutations in 85%, apoB mutations in 10% 
and PCSK9 mutations in 1% with 4% being other mutations 
that were not declared.
Ms Kate Robinson gave a powerful and erudite account of 
the diffi culties experienced by so many persons with FH, 
including the delay in diagnosis and the emotional stress. 
She and her husband had family members with heart 
disease and were not aware of their own hypercholes-
terolaemia until a diagnosis was made for her son. He was 
diagnosed with molluscum contagiosum in the fi rst few 
years of his life when he developed skin lesions. Finally a 
biopsy of the lesion revealed it was a xanthoma and he 
was diagnosed with homozygous FH because his LDL 
cholesterol was 897mg/dL (22.4mmol/L). He was placed 
on atorvastatin and ezetimibe treatment. At the age of 
5 years he developed chest pain and was found to have a 
severe stenosis in his right coronary artery. He has 
undergone apheresis since then and had to receive much 
counselling and emotional support for this weekly pro-
cedure. His sister also has homozygous FH and his brother 
is heterozygous. His father, working in the insurance 
industry, had hypercholesterolaemia (10mmol/L) and was 
on statin treatment from the age of 20 years without a 
specifi c diagnosis. He developed muscle cramps and ceased 
taking statins at the age of 31 years. He had exertional 
chest pain for a year before the diagnosis of heartburn 
changed to angina and 2 stents were placed. He was 
declined for anti-PCSK9 monoclonal antibody treatment 
but is taking atorvastatin and ezetimibe with a fi nal LDL 
cholesterol concentration of 2mmol/L. The family has done 
much for the awareness of FH at school and in the com-
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intake. The message from a genetic counsellor working in 
public health, Ms D Doyle, was that cascade testing for 
severe disorders was poorly done from medical practices 
and was not supported by medical insurance; necessitating 
cascade testing as a public health responsibility.
Many strategies are being explored to make sure that 
everyone with FH is identifi ed. Dr D Rader described that 
machine learning could fl ag candidates for FH from data-
bases. This process excluded secondary causes and hyper-
triglyceridaemia in a database of 170 million data points 
and FH was confi rmed in 87% of the fl agged individuals 
when reviewed by experts. Dr PWF Wilson indicated that 
the Veterans Administration database was also interro-
gated to ascertain the treatment success of patients with 
FH. Interestingly, white patients more likely got prescrip-
tions but black patients were much more adherent to 
prescription. His talk was shared with Dr Y Sun whose 
interest was in genetics. He mentioned that the USA had 
documented more than 1 500 pathogenic LDL receptor 
mutations. There were many variants that infl uenced LDL 
concentration, some raised concentrations but less so 
than the classical FH-causing mutations. The LDLC con-
centration ranged in these cases from 160 - 190mg/dL 
which is equivalent to 4 - 5 mmol/L. The variants across 
the population groups were shared but at different pre-
valences. Principal component analysis could separate 
African, Asian and European groups. The concluding 
remark was that the variants with mild effects on the lipid 
profi le were common and had small infl uences while the 
uncommon (pathogenic) variants of the LDLR had a 
powerful infl uence on the LDL concentration and con-
ferred the FH phenotype with its much higher risk of 
cardiovascular disease. It is not certain whether the 
strategies for fi nding cases of FH could simply be applied 
across the board in all countries.
Dr A Tybjaerg-Hansen from Denmark discussed the issue 
of polygenic severe hypercholesterolaemia. Increasingly 
since 2010, more variants in the genome are linked 
with vascular disease and/or hypercholesterolaemia. The 
number has increased from 85 - >118 as the cohorts that 
are analysed increased in size. Most of the variants had 
only a small impact on risk but there are distinct cumulative 
munity. They chose doctors who were more knowledgable 
about dyslipidaemia but did inform their medical prac-
titioners of the diagnoses in the family. They felt it was very 
important for a well-informed doctor to spend time with 
the family to explain the diagnosis, its implications and 
treatment. They were frustrated at the battles with 
medical insurance to support the treatment of FH. The 
family felt that much education was necessary at the 
medical insurance industry. Interestingly, like so many of 
the other members of the FHF, the parents referred very 
specifi cally to h-e- FH and h-o- FH. They indicated that 
the fear of statins that they sensed in the media was 
unfounded and that medication was safe and effective and 
must be commenced as early as possible.
Dr C Boileau from France gave an overview of her work in 
FH. She discovered that the FH phenotype was also 
attributable to mutations in PCSK9 and acknowledged 
several researchers who had been working on severe 
hypercholesterolaemia. She discussed variability within FH. 
Only a few genes of the 22 000 in the genome gave rise to 
the FH phenotype. The phenotype is, however, modulated 
by other genes and the environment from the fetus to the 
adult. The impact of the environment was stressed by 
indicating the doubling of LDL cholesterol levels in subjects 
with the identical mutation in the Chinese communities at 
their original country compared with Canada. The drivers 
of variability could be useful for risk assessment as well as 
therapeutic strategies. Like others at the meeting, she did 
not think that more monogenic causes of FH will be 
discovered. Of interest for LASSA members, is that the 
French mutation in PCSK9 was found in a family from a 
town in the Western Cape.
Dr M Khoury indicated that commonly encountered severe 
autosomal dominant disorders that deserve attention 
include breast and ovarian cancer (BRCA mutations), Lynch 
syndrome and FH. The estimate is that more than 1 million 
people in the USA have FH. This may be reason for 
neonatal screening. Dr Rear Admiral B Thompson indicated 
that, from a public health perspective, lifestyle interven-
tion and additional drug treatment will achieve much 
benefi t and in decreasing order of impact by intervention 
are hypertension, hypercholesterolaemia, smoking and salt 
LASSA continued
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40 years in the parents was 25%, the occurrence in the 
treated children was 1%. It must be remembered that 
the statin treatment was not with the most powerful 
statins. It must also be borne in mind that about 10% of 
the fi rst heart attacks are fatal; explaining why several 
children who were placed on treatment had already lost 
a parent.
Dr E Sijbrandts gave an overview of developments from 
clinical diagnosis to the modern “omics”. The clinical 
practice is driven by the information for the average case 
with FH even though variability is recognised by every 
clinician. Refi nement of risk prediction is important and 
genetic investigation may well provide this. He indicated 
that a recent study found that the much-used Framingham 
risk calculation was outperformed by a genetic risk pre-
diction score. There has not been much forthcoming from 
more novel biochemical markers of risk. The approach may 
need to change: atherosclerosis is a disease and should be 
modifi ed rather than its being an event at which stage 
intervention should be considered and may be too late to 
be of real benefi t.
effects. In general a high polygenic risk score of genes with 
minor infl uence raised LDLC by 0.8mmol/L but this does 
not usually approach the LDLC values seen in FH. 
Incidentally, these scores aggravated the LDLC con-
centration in FH subjects and could account for additional 
risk in FH. She also indicated that in some families in the 
Danish population, high Lp(a) demonstrated a dominantly 
inherited hypercholesterolaemia with premature heart 
disease and on these grounds the diagnosis of FH could 
be made. In the general population, LDL hypercholes-
terolaemia was explained by polygenic scores in 23% 
whereas monogenic hypercholesterolaemia explained 
<2%. The monogenic disorders generally have much higher 
LDLC than the polygenic disorder.
Dr S Kathiresan discussed genes infl uencing plasma choles-
terol concentration and vascular risk. A relatively recent 
contribution to hypercholesterolaemia is the linking of the 
ABC transporter G5 and G8 variants to hypercholes-
terolaemia. Variants in this dimeric transporter, expressed 
in the enterocyte and hepatocyte, affect sterol uptake and 
excretion and account for about 0.6 mmol/L in the 
cholesterol concentration. A distinction was made between 
polygenic risk scores for hypercholesterolaemia and poly-
genic risk scores for coronary artery disease. The latter 
category does include a few lipid genes but the impact of 
the lipid genes is probably best described by the plasma 
total or LDL cholesterol concentration while the coronary 
disease risk factors are not subject to such a simple and 
inexpensive biochemical test. Dr Kathiresan applied genetic 
investigations to the UK Biobank project. The odds ratio for 
coronary disease in people with mutations conferring FH 
was 6 across the age range, while for polygenic hyper-
cholesterolaemia it ranged from 1 - 20 according to the 
number of adverse genes. Within FH it was interesting to 
view the cumulative occurrence of premature heart disease: 
those with a low score had a 20% event rate and those 
with an high score had a 80% event rate in the 7 decades 
of life. Dr Kathiresan quoted the recent publication from a 
Dutch study that analysed the premature ischaemic heart 
disease occurrence in the parents who antedated the use 
of statins and the occurrence in children who were treated 
with statins and have now reached 40 years of age. 
Whereas the occurrence of heart attacks by the age of 
Continued on page 114
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paediatricians and medical practitioners are not aware of 
the reference ranges for dyslipidaemia in children.
Dr N Wenger from Atlanta discussed the integration of 
science, policy and behaviour. She emphasised the need for 
pre-pregnancy counselling for couples, as well as the need 
to discontinue statins at least 4 weeks before the planned 
conception. Lifestyle changes are to be recommended to 
pregnant women with FH and only bile acid sequestrants 
should be used. She was uncertain about breast feeding 
while taking statins. There was an interesting “heart owner 
instruction manual” proposed for patients. The heart is 
described as a fi st-sized pump weighing <500g but per-
forming 100 000 beats per day and putting out 7 200 litres 
per day into about 96 000km of vessels. The warranty is 
about 81 years for women and 71 years for men but only 
if serviced with checks (mass, BP, LDL, HDL, TG, Lp(a), 
CRP) at regular intervals and appropriate intervention is 
taken in response to problems detected along the service 
plan. In-between service checks the owner needs to follow 
evidence-based advice: to walk daily (30 minutes), to 
consume healthy fuel/food, and not to raise the load 
(achieve ideal body mass).
The last formal talk was by Dr K Bibbins-Domingo whose 
interest is public health. She was a participant in the US 
Preventive Service Task Force. This organisation makes 
about 12 recommendations per year based on reviewing 
evidence but admittedly has no authority over care 
providers. However, the feeling is for category A and B 
evidence, copayment should not be required. Regarding 
cholesterol: statin treatment for primary prevention is 
category B though FH was not specifi ed. Such specifi cation 
is probably required as Dr Bibbins-Domingo did indicate 
that the intervention should be in agreement with the 
degree of risk. The recommendation about testing children 
for hypercholesterolaemia was a grade I which means 
inadequate evidence. This might require a special comment 
for FH as the risk is high and the evidence of benefi t from 
intervention in FH children is available.
The next day presented an opportunity for delegates from 
various countries to meet. Each delegate described the 
main activities around FH and how they relate to the call 
Dr R Santos, president of the International Atherosclerosis 
Society described the status of FH in the 10 country study 
that was sponsored by the IAS. The study indicated that 
FH was diagnosed in <4% of expected cases in the 
participating countries. The more severe hypercholes-
terolaemias (LDLC >7mmol/L) had the highest detection 
rate of mutations in the LDLR, apoB and PCSK9 genes. In 
poorer countries, treatment is often not available at all 
and it was suggested that severe disorders such as FH 
should gain support for treatment from the government as 
part of more universal healthcare. In LDL hypercholes-
terolaemia of >4mmol/L as well as in FH, primordial 
preventive treatment is advocated in youth according to 
Dr L Hayman. The poor adherence to statin prescription 
was discussed by Dr F Rodriguez. Patient factors in this 
problem relate to a distrust in statins as well as a problem 
with polypharmacy. The medical profession may aggravate 
the problem of adherence by not monitoring and intensi-
fying treatment. There is also a problem in the healthcare 
system that discourages adherence, especially when 
copayments need to be made and when there is a 
bureaucratic burden to this. Disparities in healthcare were 
emphasised by Dr L Sperling who compared the various 
addresses in Atlanta which denote socio-economic dif-
ferences. There is no doubt that ethnic minorities, women, 
and lower economic status infl uence the treatment of 
patients with FH. One of Dr Sperling’s patients came on 
the stage and gave an account of her original general 
practitioner who ascribed her recurrent and later persistent 
Achilles tendonitis to “pump heels”. Her severe hyper-
cholesterolaemia, discovered at blood transfusion, had 
antedated this problem. She developed premature 
coronary disease and the diagnosis of FH was fi rst 
mentioned after 18 angiograms when a triple vessel bypass 
operation was performed. She had intolerance to statins 
at higher doses but is on a low dose of a statin. After much 
effort, she is now receiving apheresis and a PCSK9 
neutralising agent.
An update on FH was given by Dr R Alonso for South 
America which continent still has very strong ties to Spain. 
Dr A Peterson discussed paediatric and primary health care 
management of FH. One of the problems was that few 
LASSA continued
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LASSA will strive to improve the awareness and manage-
ment of FH in South Africa and aims to contribute to the 
cause for the African continent. The expertise should pre-
ferable be honed before PCSK9 neutralisers reach our 
market. To this end, we aim to run another educational 
course in May 2020 over a few days in Cape Town. The 
proposed date is 18 - 20 May and we hope to raise funds 
so that delegates are only responsible for travel arrange-
ments to attend and a registration fee. We had generous 
unconditional support from some pharmaceutical com-
panies this year. We also hope that medical schemes will 
support and participate as their panels will need to make 
decisions on management of FH.
The LASSA committee is concerned about the lack of 
support for lipidology and will soon suggest adjustments to 
our constitution to encourage growth of this discipline; 
especially if we are supported for reaching out to other 
medical schools in Africa. We have already gained one 
member from Uganda and have interested parties in Ghana 
and Nigeria. We certainly would welcome the connexion 
as, by a simple calculation, there are more than 2 million 
persons with FH in sub-saharan Africa.
David Marais
to action that the FH Foundation is planning to submit 
to an international medical journal as well as to the WHO. 
A representative from the WHO attended the session. It is 
hoped that the offi cial, authoritative approval and recom-
mendations from the WHO will create a minimum standard 
to which developing countries will adhere It was worth 
attending the meeting about FH, a common, severe and 
treatable condition that should be diagnosed as a specifi c 
entity. Unfortunately the advances in insight into the causes 
of severe hypercholesterolaemia and the improved treat-
ment with successful reduction of vascular events have not 
been translated well into medical practice. It seems as if 
there is a world-wide problem to do this serious disorder 
justice. It is thus necessary for the medical profession as 
well as the patient lobby to improve matters so that all 
persons with FH can be identifi ed and treated from an 
early age.
In the majority of the cases, especially with early inter-
vention, statins and ezetimibe will suffi ce for heFH and only 
a minority will require expensive agents. While it is possible 
that risk prediction will be refi ned in FH in the future, all 
severe hypercholesterolaemia cases thought to be FH 
should be taken seriously and should receive support.
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sa heart
SUMMARY OF RECENT SHARE 
ACTIVITIES MID-AUGUST 2019 - 
MID-NOVEMBER 2019:
 ■ Annual leave days taken: Tuesday 01 October 2019 (1 
working day), 
 ■ Annual leave request/planning: 29 November, 17 
December 2019 - 3 January 2020 (12 working days)
 ■ Sick leave: 18 - 27 September 2019 (8 working days for 
cervical fusion and disc replacement)
 ■ Highlights: Abstracts presented at ESC 2019 and 
SA Heart® Congress 2019 
TAVI:
 ■ 231 TAVI were captured across South Africa in 2018, 
and as at mid-November last year that number has 
been equalled (231 TAVIs captured in 2019), with a 
high number of applications in recent months (171, up 
from 145 last quarter), it may be possible to reach 245 
for 2019 in total. There are still some outstanding 
entries for Sunninghill and Union but these are in the 
process of being captured.
 ■ Currently just under 1 290 patients are entered into 
the DB, and >930 TAVIs have been entered, an 
increase of 30 in the last quarter. 164 patients have 
exited without a TAVI, mostly due to declined funding. 
The number of patients awaiting decisions for funding 
(n=171) does include many who have outstanding 
funding decisions due to lack of follow up at sites on 
patients who have been declined funding for TAVI. 
This will be a focus area in coming months, Sunninghill 
has requested the design of a template to be emailed 
to referral doctors and patients to assist with the high 
volume of patients they need to follow up. If this proves 
successful it will be rolled out to all sites for those who 
choose to use it.
 ■ Ongoing follow up and QA at all sites. Liaison with 
Kosta re patient record duplication by users.
 ■ Investigation into date-time errors at Union.
 ■ Liaison with Industry regarding problems with Funders.
 ■ Training for new sites at Milpark, Ethekwini, ZAR, 
training new person at Dawood practice Vincent 
Pallotti.
 ■ SA Heart® and ESC abstract posters: QA, preparation 
and analysis of data, poster design, and presentation at 
those meetings. Best Poster Award for PASCAR/
SA Heart®.
TAVI Challenges:
 ■ Chris Barnard MH: Lindy in Dr Horak’s rooms has 
been assisting with capture of this with the help of 
Christine in Dr Koen’s offi ce. This remains a problem 
site but has low volumes so low impact. 
 ■ Union: Recently the tech at Dr Zambakides practice 
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Vincent Pallotti - Team 2 12
Vincent Pallotti Life 133
Zuid Afrikaans 1
Grand Total 1 289
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10 captured and 33 still outstanding, this improvement 
is welcome and will be encouraged further. 
 ■ Follow up data is long outstanding at most sites. A 
follow up template is being developed to assist with 
this. 
 ■ Practices (especially referral practices) don’t always 
have access to patients for follow up data as patients 
return to their referral practices. Follow up can be done 
telephonically when necessary and site staff have been 
advised to do this when needed. 
SHARE – SAFFR – AFIB/FLUTTER 
REGISTRY:
 ■ Database development now completed and tested by 
EMS. PIs added as users to the Test DB, PIs tested the 
system with anonymized data for dataset completeness, 
and suggested modifi cations have been completed. 
 ■ Ethics approval given in for Dr Mpe site. All other sites 
need to complete GCP and site validation to qualify for 
inclusion and to be added to the Pharma-Ethics 
approval. 
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Vincent Pallotti - Team 2 11
Vincent Pallotti Life 97
Grand Total 933
 ■ Dr Mpe has started capturing cases into the registry for 
Pretoria Heart site.
 ■ Potential sites have been approached regarding parti-
cipation, and potential Investigators are renewing their 
GCP certifi cation where needed, and gathering docu-
ments for Ethics submissions for the additional sites. 
 ■ Due to RWC screening times were affected for all 
sessions and only Dr Mpe, Jane Moses, and a repre-
sentative from Professor Nqoba’s offi ce were able 
to attend Investigator’s meeting scheduled for 
SA Heart® Congress. Positive feedback from Professor 
Nqoba’s representative, request for CRFs to be used in 
their setting, Jane Moses requests references for her 
Ethics application.
CDM REGISTRY
Registry has been closed for enrolment, no further patient 
enrolment planned. Feriel Azibani from Hatter Instititute 
was tasked with producing a manuscript on the existing 
data, but as she has now taken extended leave, Elizabeth 
has obtained permission from Professor Sliwa to start with 





Number of participants enrolled – 
further enrolment closed 
136 
Number of participants enrolled since 
last Progress report 
0 
2. Cumulative summary of participants  
Number of participants currently 
active on the study 
27 
Number of participants 
completed study 
56 
Number of participants with 
overdue information 
27 




Groote Schuur 112 
IALCH Inkosi Albert Luthuli 
Central Hospital 
4 
Steve Biko Academic 20 
Grand Total 136




 ■ Rapid deployment valve: Edwards device still requires 
approval. To follow up in 2020 – no movement 
currently.
 ■ HF/CRT device registry: No movement. Elizabeth 
approached Jane Moses again, met in CT to discuss 
responsibilities and workload, she has not yet 
responded. 
 ■ PCSK9i registry: There is willingness to do registry, 
now awaiting drug registration process to be completed, 
expected early this year. 
 ■ Mitral Clip registry: Device still needs to complete 
registration in SA. 
SA HEART® GENERAL:
 ■ Assisted with setup and presence at ESC.
 ■ Evaluation and research for new technical equipment 
for Erika.
 ■ Assistance with evaluation of new membership systems. 
 ■ Met with SASA to discuss collaboration and synergy.
 ■ Attendance of Associations Executives conference, 
evaluation of strategies, membership and marketing for 
SA Heart®.
 ■ Assistance with preparation and attendance at 
SA Heart® Board and NAC meetings.
Elizabeth Schaafsma and Professor Mpiko 
Ntsekhe, Chairperson, SHARE Committee
SHARE REGISTRY UPDATE continued
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We are deeply saddened to announce the passing of 
Professor Lionel Opie, co-Founder of the Hatter Institute, 
University of Cape Town.
Lionel Opie, internationally recognised as one of the world’s 
foremost scholars of cardiovascular disease, was born in 
Hanover, a small Karoo town, in 1933. After qualifying in 
medicine at the University of Cape Town in 1955, he 
realised his ambition and went to Oxford as a Rhodes 
scholar in 1957, where he earned a DPhil and trained with 
2 Nobel prize winners, Professor Sir Hans Krebs at Oxford, 
and Professor Sir Ernst Chain at Imperial College, London.
He returned to Cape Town in 1971, his research being 
supported by Professor Chris Barnard, before being 
awarded a Medical Research Council Unit for Ischaemic 
Heart Disease (1976 - 1998). 
In 1999, together with Professor Derek Yellon (University 
College London), he established the Hatter Institute at the 
University of Cape Town as a sister to the Hatter Institute 
at University College London. He remained the Director 
until his retirement in 2010.
In recognition of his prolifi c publication record, he was 
honoured by the University of Cape Town in 2012. His 
major books are Drugs for the Heart (eds Opie and Gersh), 
and Heart Physiology from Cell to Circulation that won a 
UCT book award. This book is often referred to as the 
“Bible in Cardiology”.  His books have been used worldwide 
for teaching and research purposes.  
In 2006 he was given the highest award by the President 
of South Africa, the Order of Mapungubwe, silver, for 
“Excellent contributions to the knowledge of and achieve-
ment in the fi eld of cardiology”. In 2008 he was elected 
a grade A1 scientist by the National Research Foundation 
(NRF) of South Africa and received an NRF Lifetime 
Achievement Award in 2014.
Professor Opie was highly regarded and well respected by 
his peers, colleagues and students for his work ethic, 
humility, integrity and passion for research.  He was a great 
mentor and distinguished teacher as is evidenced by the 
very successful career paths of his former students, many 
of whom now hold key positions around the world.
He will be greatly missed by all, particularly the staff and 
students (both past and present) of the Hatter Institute for 
Cardiovascular Research in Africa, who feel privileged to 
have worked with him and are forever grateful for the 
wonderful legacy he has left behind.
He is survived by his wife Carol, daughters Jessica and 
Amelia, and their families.




n 2017 I had the opportunity to take part in the 
prestigious Biomedical Sciences Exchange Programme 
(BMEP) funded by the German Academic Exchange 
Service (DAAD), which enabled me to pursue a research 
fellowship at the Hatter Institute for Cardiovascular 
Research in Africa (HICRA), under supervision of Professor 
Karen Sliwa. For this academic year, I paused my medical 
studies at Hannover Medical School (MHH) in Germany 
and joined the Cardiac Disease in Maternity (CDM) 
research group in Cape Town.
I was involved in a clinical research project on women with 
peripartum cardiomyopathy (PPCM). PPCM is an idiopathic 
form of dilated cardiomyopathy, which occurs in previously 
healthy women towards the end of pregnancy or within 
fi ve months following delivery.(1) 
As part of my clinical research fellowship, I regularly 
attended the dedicated Cardiomyopathy Clinic as well as 
the Cardiovascular Disease in Pregnancy Clinic led by 
Professor Sliwa at Groote Schuur Hospital’s Cardiac Clinic. 
For my research project, I studied the 12-lead electro-
cardiogram (ECG) of women with peripartum cardio-
myopathy. Though previous research has shown that the 
ECG is frequently abnormal in PPCM, the aim of my project 
was to identify whether any electrocardiographic features 
would be prognostic and/or be useful in the risk-stratifi ca-
tion of women with this condition. With the tremendous 
help of Dr Charle Viljoen, a Cardiology fellow at Groote 
Schuur Hospital, we analysed hundreds of ECGs of patients 
with PPCM and set up an electronic database for the large 
Cape Town PPCM registry. Subsequently, we performed 
the statistical analysis and could show that, in this cohort, 
sinus tachycardia and prolonged QTc predicted poor 
outcome, whereas sinus arrhythmia was associated with 
event free survival. In May 2018, we were fortunate to 
present our research at the European Society of Cardiology 
(ESC) Heart Failure Congress in Vienna and shortly after 
we published our results in the International Journal of 
Cardiology (IJC).(2) 
The Hatter Institute for Cardiovascular Research in Africa 
(HICRA), within the Department of Medicine at the 
University of Cape Town (UCT), is a vibrant research hub 
with a strong focus on translational research. It comprises 
fi ve research groups, namely the Cardiac Disease and 
Maternity Group, Cardiovascular Genetics Group, Cardio-
protection Group, Lipid Research Group and Heart of 
Africa Projects. All groups consist of internationally 
renowned senior researchers as well as (post-graduate) 
students from South Africa and many other African 
countries. I was truly impressed by the weekly journal club, 
where the students gave paper presentations on various 
topics in cardiology and present data updates of their 
research. The discussions afterwards always stimulated 
new research ideas and collaborations. And I will always 
fondly remember the friendly and familial atmosphere at 
the Hatter Institute.
EXCELLENT RESEARCH EXPERIENCE AT THE HATTER INSTITUTE 
FOR CARDIOVASCULAR RESEARCH IN AFRICA (HICRA)
Presentation of our research at the European 
Society of Cardiology (ESC) Heart Failure Congress 
in Vienna, May 2018. From left to right: Julian 
Hövelmann, Karen Sliwa and Charle Viljoen.
Weekly research meetings of the Cardiac Disease in 
Maternity Research Group at the Hatter Institute. 
From left to right: Karen Sliwa, Julian Hövelmann, 
Vitaris Kodogo, Johann Baard, Olivia Briton.
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Over and above my academic and research commitments, 
the scholarship also enabled me to truly get to know the 
city of Cape Town, the different cultures living in South 
Africa and to understand the socioeconomic challenges, 
which they are faced with every day. I really enjoyed the 
amazing hiking trails and trail running routes around Table 
Mountain and the abundant coastlines, with endless 
opportunities for swimming and water sports. On the 
weekends, I also had time to explore the true beauty South 
Africa and the Western Cape in particular.
A very memorable aspect from my time in Cape Town was 
my participation in the SHAWCO outreach clinic. In this 
student run initiative from the University of Cape Town, 
medical students reach out to the poor communities in 
and around Cape Town to deliver free medical treatment 
and consults under supervision of a doctor. The visits in the 
township clinics gave me insight into poverty related disease 
conditions, which I had never seen before during my studies 
in Germany. The personal interactions I made there, 
certainly left me very humbled and thoughtful and will leave 
impressions that I will not forget in my future practice as a 
medical doctor.
I am truly grateful for the very warm welcome, I received at 
the Hatter Institute, the University of Cape Town, and the 
UCT Cardiac Clinic. During this time, I had the opportunity 
to meet so many excellent and passionate researchers and 
medical doctors and made excellent friendships, which will 
always maintain me a special personal connection to Cape 
Town and South Africa. I hope that this report will 
encourage others to apply for similar scholarships and that 
it will promote further research exchange between 
Germany and South Africa. There is so much that we can 
learn from each other.
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Julian Hoevelmann (German Elective Student)
I was 
involved 
in a clinical 
research project 
on women.
The Hatter Institute’s 2017 End of Year function at 
Thula Thula Private Game Reserve.
SHAWCO: A student run initiative of the University 




would like to thank the SA Heart® Association for the 
generous contribution in the form of a travel scholar-
ship, which allowed me to attend the European Society 
of Cardiology’s Congress in Paris from 31 August - 
4 September 2019. Last year’s ESC Congress was held 
together with the World Congress of Cardiology, at the 
Porte de Versailles Exhibition Centre on the outskirts of 
the City of Light. This annual congress is the largest of its 
kind in the world and attracted 33 000 clinicians, scientists 
and delegates from industry last year. The theme of the 
congress was “Global Cardiovascular Health”. I would like 
to refl ect on this very memorable occasion.
There was an important South African presence at last 
year’s congress. Professor Karen Sliwa, who is the Director 
of the Hatter Institute and the current president of the 
World Heart Federation, introduced the Bongani Mayosi 
Memorial Lecture. Dr George Mensah, who was a colleague 
and friend of the late Professor Mayosi, delivered an 
inspirational lecture entitled “Cardiovascular health 
research, training and capacity building in low- and middle-
income countries”. He encouraged the audience to work 
together to endeavour the eradication of rheumatic fever 
and rheumatic heart disease.
As part of our research activities at the University of Cape 
Town and the Hatter Institute for Cardiovascular Research 
in Africa, I had the privilege of attending the Peripartum 
Cardiomyopathy working group meeting on the Saturday 
afternoon. On the Sunday afternoon, I had the opportunity 
to present our poster entitled “Prospective randomised 
study on implanted cardiac rhythm recorders in pregnant 
women with symptomatic arrhythmia and/or structural 
heart disease”. It was at the same time inspiring and fulfi lling 
to attend friends and colleagues’ poster and oral pre-
sentations of various research projects that were conducted 
in South Africa and further afi eld. 
There were several exciting late breaking trial sessions at 
last year’s ESC congress. To name but a few:
 ■ COMPLETE showed that revascularisation of non-
culprit lesions in patients with STEMI led to a signifi cant 
reduction in cardiovascular death or recurrent myo-
cardial infarction.(1)
 ■ DAPA-HF found that dapaglifl ozin, a sodium-glucose 
co-tranporter-2 (SGLT-2) inhibitor, led to a substantial 
reduction in the risk of worsening of heart failure or 
cardiovascular death in patients with Heart Failure with 
reduced Ejection Fraction (HFrEF), even in patients 
without diabetes mellitus.(2)
 ■ Though PARAGON-HF narrowly missed its primary 
endpoint (i.e. reduction of cardiovascular death or HF 
hospitalisation) for patients with Heart Failure with 
preserved Ejection Fraction (HFpEF) who received 
sacubitril/valsartan, there were subgroups of patients in 
which the ARNI did show benefi t (i.e. in women and 
those with ejection fraction of 57% or lower).(3) 
I was looking forward to learning the outcome of 
PARAGON-HF, as we screened and enrolled patients at 
Groote Schuur Hospital to participate in this trial. Though 
the fi rst results are disappointing for the quest of fi nding 
an effective treatment for HFpEF, further post hoc analyses 
are awaited, which might further delineate which patients 
with HFpEF might benefi t from an ARNI.
The ESC’s EURObservational Research Programme 
(EORP) hosted a symposium during which the results of 
several registries were presented. The endocarditis (EURO-
endo) registry found that endocarditis remains a disease 
with high mortality and morbidity, especially in patients that 
required valvular surgery, but were not operated.(4) Similarly, 
the peripartum cardiomyopathy (PPCM) registry reported 
that adverse outcomes remained very prevalent at 6-month 
follow up, despite most patients receiving optimal medical 
therapy.(5) According to the Registry Of Pregnancy and 
Cardiac Disease (ROPAC), patients with uncorrected 
congenital heart disease had worse maternal and foetal 
outcomes than their counterparts who had previously 
undergone corrective cardiac surgery.(6) 
Several sessions were dedicated to the release of the 2019 
Clinical Practice Guidelines. In the absence of contra-
indications, non-vitamin K antagonist oral anticoagulants 
(NOACs) are now recommended as the fi rst choice 
anticoagulant for Pulmonary Embolism (PE).(7) Similarly, in 
patients with diabetes, NOACs are now preferred over 
warfarin in the management of atrial fi brillation. Catheter 








ablation plays a much more important role in the con-
temporary management of Supraventricular Tachycardia 
(SVT), than in the 2003 ESC guidelines.(8) These recom-
mendations would currently be diffi cult to implement in the 
South African public sector, where NOACs are not yet 
freely available and centres doing catheter ablations are 
very limited. The term “chronic coronary syndromes” will 
be replacing the term “stable coronary artery disease”. In 
that regard, coronary CT angiogram is now preferred to 
the exercise ECG to diagnose coronary artery disease in 
symptomatic patients in whom obstructive CAD cannot be 
excluded by clinical assessment alone.(9)
This was the fi rst time that I attended the ESC congress. I 
was impressed by the great variety of topics that were 
discussed and presented, as well as the superb quality of 
the sessions. Over and above gaining new knowledge, the 
congress also allowed for networking and exchanging 
research ideas with colleagues from all over the world. I 
wish to thank Erika Dau for being such an outstanding 
ambassador at the SA Heart® booth.
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would like to extend my sincerest gratitude to the 
HeFFSA executive committee for awarding me the 
HeFFSA travel grant to facilitate my travel to the ESC 
congress in Paris last year. The time spend was tremen-
dously rewarding and fruitful. I’d like to summarise my 
experience.
Last year saw the ESC Congress join forces with the World 
Heart Federation for a combined congress which kicked off 
on 31 August. The theme of last year’s congress: “Global 
Cardiovascular Health” came as a breath of fresh air 
together with the promise from World Heart Federation 
president, Professor Karen Sliwa to herald an era of joint 
commitment by these 2 organisations to global health. The 
venue was spacious, comfortable and very easy to reach 
by Paris metro. 
My personal Scientifi c programme highlights were: 
2019 ESC CLINICAL PRACTICE 
GUIDELINES
Five new Clinical practice guidelines were launched: Supra-
ventricular tachycardia, Chronic coronary syndromes 
(previously called Stable coronary disease), Diabetes, 
Dyslipidemia, Acute Pulmonary Embolus. 
The Chronic coronary syndrome guidelines have markedly 
revised the pre-test probability of disease to try and give a 
more realistic assessment of the likelihood of CAD. The 
model in the previous version of the guidelines tended 
to overestimate disease. The new guidelines suggest that it 
is safe to defer investigation in patients with a pretest 
probability of <15%, though it can still be considered if the 
symptoms are limiting. 
Furthermore, the new guidelines gave more prominence 
to the role of Coronary CT angiography to confi rm the 
diagnosis as an initial test, while the role of exercise testing 
without imaging has been downgraded from a class I to a IIb 
indication – to be used IF no functional imaging testing is 
available. 
THE RESULTS OF THE DAPA-HF TRIAL
Prior trials, including EMPAREG showed that SGLT2 
(sodium-glucose co-transporter 2) inhibitors in addition to 
effectively treating diabetes, also reduced the risk of patients 
developing heart failure. These benefi ts are seen raljklpidly, 
even within weeks. 
DAPA-HF aimed to assess if these drugs can be used to 
treat patients with established heart failure including those 
without diabetes? A total of 4 744 patients from 20 
countries with heart failure with reduced EF (HFrEF) were 
randomised to 10mg dapaglifl ozin vs placebo in addition 
to standard care. The primary end-point was a composite 
of worsening heart failure or death from cardiovascular 
causes, analysed as a time-to-fi rst-event. About 50% of the 
patients did not have diabetes. 
Dapaglifl ozin showed a statistically signifi cant reduction in 
the risk of the composite endpoint by 26%. (p<0.00001). 
On individual analysis, the risk of worsening heart failure 
was reduced by 30% and the risk of CV death reduced 
by 18%.
OTHER USEFUL TALKS
A number of useful tracts for younger clinicians and budding 
researchers dealt with issues such as: How to fund your 
project, How to get your article published in a high-end 
journal – discussions with the editors... These and many 
more related topics were of particular practical use. 
ESC REPORT BACK: HEFFSA TRAVEL GRANT 
Charle Viljoen, Blanche Cupido and Erika Dau at the 
SA Heart® Booth.
125
I attended a number of talks relating to Cardio-oncology – 
a growing fi eld gaining increasing recognition and the 
importance of adequate screening and what that screening 
would entails, was covered in a number of talks.
MY CONGRESS INVOLVEMENT WAS 
TWO-FOLD: 
 ■ I have recently been nominated to serve on the ESC 
Global Affairs Committee as the Deputy Ambassador 
for Africa, a branch of the ESC currently led by 
Professor Rick Grobee from the Netherlands. At the 
ESC congress, we had a number of useful meetings 
with a few of the cardiac societies in Africa. These 
meetings served as a needs assessment for the ESC to 
ascertain how to best serve the cardiology community 
in Africa. A number of very useful ideas emerged which 
will be implemented over the next 2 years. Further-
more, the collaboration between SA Heart® and the 
ESC not only continues but will strengthen due to a 
few collaborative efforts in the near future. 
 ■ I moderated a poster session on heart failure together 
with Professor John Cleland. I also presented a plenary 
talk entitled: “Which is the bigger villain: Fats or 
carbohydrates?”  This is always a rather emotive topic, 
but good conversation and feedback was received.
These are just a few of my personal highlights. Thank you 
once again for the opportunity for this funding.
Dr Blanche Cupido
ESC Logo at the Opening Ceremony.
A lovely sunny Parisian day at the Jardin Tuileries,
COVID-19 NEWS
Please consult the SA Heart® webpage regularly where we 
are posting COVID-19, mostly locally relevant, updates. 
Please also contribute should you have information of 
importance to other members and CVD health care workers. 
You can email info@saheart.org with your contribution.
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INTRODUCING COSOSA - 
THE CARDIO ONCOLOGY SOCIETY 
OF SOUTHERN AFRICA
Cancer and cardiovascular disease (CVD) are the 2 most 
common causes of death and disease worldwide! The 
incidence of both cancer and cardiovascular disease 
increases with age. With increased life expectancy, the 
burden of both diseases will increase substantially over the 
next decade. Physicians and ancillary staff frequently provide 
care for patients with cancer and cardiovascular disease. 
Some cardiac diseases predate the diagnosis of cancer, 
whereas other conditions like chemotherapy-induced 
cardiomyopathy and radiation-related heart disease are 
directly related to the cardiotoxic side effects of cancer 
therapy. Cardio-oncology has developed as a new discipline 
within cardiovascular medicine as a result of the cardiac and 
vascular adverse sequelae of cancer therapy advancement. 
Clinically, these challenges are best addressed by a multi-
disciplinary approach in which cardiovascular medicine 
specialists work closely with oncologists in the care of 
patients with cancer as well as cancer survivors. 
Consequently, to cater for the need of a local multi-
disciplinary constituent body, this led to the formation of 
the Cardio Oncology Society of Southern Africa (COSOSA) 
under the leadership of Dr YT Singh (Cardiologist), Dr Ria 
David (Medical Oncologist) and Dr Ines Buccimazza 
(Specialist Surgeon – Breast and Endocrine). The purpose 
and vision of the society is to advance the development of 
Cardio-Oncology in all its aspects in Southern Africa to 
make sure that the cancer patients are not only cured 
of their cancer but do not develop cardiovascular disease. 
The COSOSA Executive gained invaluable insight from 
colleagues in Cardiology and Oncology at peer-group 
meetings in Johannesburg and Cape Town and we look 
forward to expanding our leadership to involve various 
specialities across Southern Africa. 
The Objectives of COSOSA is creating awareness through 
training and education programs aimed at Healthcare 
Professionals caring for patients with cancer to make sure 
that such patients not only receive optimal care for their 
cancer but are timeously diagnosed and treated for 
cardiovascular complications arising either form cancer 
therapy or comorbidities that exist concurrently with the 
patient’s cancer. Advising governmental and non-govern-
THE CARDIO ONCOLOGY SOCIETY OF SOUTHERN AFRICA
COSOSA Directors: Dr YT Singh (Cardiologist), Dr Ines Buccimazza (Specialist Surgeon – Breast and Endocrine) and 
Dr Ria David (Medical Oncologist).
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mental organisations on cardio-oncology matters and 
policies. Liaising with other organisations in the fi eld on a 
global level. Advancing the interests of its members. 
COSOSA, an affi liate of the International Cardio-Oncology 
Society (ICOS), is the fi rst Cardio-Oncology Society in 
Africa and will be hosting Africa’s fi rst Cardio-Oncology 
Conference in Durban on 7 March 2020. We anticipate 
approximately 200 delegates from cardiology, haematology, 
oncology, surgery, internal medicine and general practice 
to attend. The conference will also be open to allied 
health care professionals with an interest in the effects of 
cancer treatment on the heart. The meeting will provide 
excellent opportunities for interdisciplinary learning, inter-
action and networking. 
The organising committee has secured Professor Daniel 
Lenihan as a keynote speaker for the conference. Professor 
Lenihan is a Professor of Medicine and Director of the 
Cardio-Oncology Center of Excellence, in the Division of 
Cardiovascular Medicine, at the Washington University in 
St. Louis, USA. He is also the president of ICOS. Professor 
Eric Harrison, Head of Cardiology and Cardio-Oncology, 
University of South Florida, USA is also confi rmed as faculty 
amongst the excellent South African faculty. 
The Journal of the American College of Cardiology (JACC) 
published the fi rst issue of JACC: CardioOncology in 
September 2019, with Professor Bonnie Ky (University of 
Pennsylvania) as Editor-in-chief. This is an open-access 
journal publishing articles on Multidisciplinary care of cancer 
patients and survivors at risk for cardiovascular disease. 
Register online to attend the inaugural COSOSA Con-
ference on 7 March 2020 in Durban. The Conference 
programme and International Faculty Biographies can be 
viewed on the Registration Page. 
More information on further COSOSA Educational initia-
tives will be shared in the near future. 
For more information on COSOSA 
or to get involved in the activities and 
leadership, please contact Wihan Scholtz 
at the Society Offi ce on 
email info@cososa.org or 
call +27 (0)84 569 8244. 
Dr YT Singh
Dr Eric Harrison (ICOS President), Dr YT Singh 
(COSOSA Chairperson) and Dr Stephen Caselli 
(ICOS Executive Director) at the 3rd Global Cardio-
Oncology Summit, 3 - 4 October 2019, Brazil. 
Professor Bonnie Ky ( Editor-in-chief, JACC: 
CardioOncology) with Dr YT Singh and Professor 
Daniel Lenihan (ICOS President).
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TRAVEL SCHOLARSHIPS OF THE 
SOUTH AFRICAN HEART ASSOCIATION
Applications for the SA Heart® Travel Scholarship for the second term in 2020 are invited to reach the SA Heart® 
Office by 30 June 2020.
The scholarship is for the value of up to R25 000.00 for international meetings and R10 000.00 for local meetings.
This scholarship is available to all members residing in South Africa. It is primarily intended to assist junior 
colleagues to ensure continued participation in local or international scientific meetings or workshops.
REQUIREMENTS
■ Applicants must be fully paid-up members for at least 1 year.
RECOMMENDATIONS
■  Early and mid-career applicants (<5 years post-qualification as specialist and/or <5 years post-PhD qualification).
■  Acceptance of an abstract/poster presentation at the scientific meeting to be attended.
CONDITIONS
■  Awards will not be made for conferences or workshops retrospective to the application submission deadline. 
If the conference is taking place within six (6) weeks following the submission deadline, please indicate this in 
the appropriate place on the application form.
■  It is not a requirement for the abstract to be accepted by the conference travel application closing date. 
Should the acceptance of the paper, including proof of registration not be available at the time of submission 
of the application, then a provisional award may be made pending receipt of the acceptance of the paper.
■  Please ensure that applications are made as well in advance as possible (preferably at least 6 months prior 
to the conference date).
■  Applicants may only submit 1 application every second year. The scholarship is for the value of up to 
R25 000.00 for international meetings and R10 000.00 for local meetings.
■  Awards are only made in the event that a paper or a poster is being presented or in the event of a workshop 
attendance, if the reviewers deem the workshop attendance to be of high impact and consequently of benefit 
to the SA Heart® community.
■  The applicant must ensure that the application is fully completed including the requirements as detailed in the 
checklist section. Applicants are asked to be concise and to only include applicable and relevant information.
■  Awards are granted for 1 specific conference. Should that specific conference be cancelled or the full amount 
allocated not utilised for any reason, then the funds must revert to SA Heart®; and
■  A written report on the relevant congress attended will need to be submitted by the successful applicant 
within 6 weeks of attending the congress. The congress report will be published in the South African Heart 
Association Newsletter.
SUBMISSION REQUIREMENTS
■   For more information and application forms, please visit https://www.saheart.org/cms-home/category/39.
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accepted by the relevant congress organising committee, 
the applicant will forfeit his or her sponsorship towards 
the congress. (Application can however be made well in 
advance of the relevant congress but will only be awarded 
on acceptance of the abstract.) A written report on the 
relevant congress attended will need to be submitted by 
the successful applicant within 6 weeks of attending the 
congress. The congress report will be published in the 
South African Heart Association Newsletter.
Applications should be sent to Dr Alfonso Pecoraro, 
President of the Western Cape branch of the South 
African Heart Association, Division of Cardiology, Tyger-
berg Hospital, Francie van Zijl Drive, Tygerberg 7505; or 
alternatively email: pecoraro@sun.ac.za.
Previous recipients of this prestigious award include 
Sandrine Lecour, Roisin Kelle, Liesl Zühlke and Prof Hans 
Strijdom.  
Applications close on 31 January 2021.
LOUIS VOGELPOEL TRAVELLING SCHOLARSHIP
A gifted and 
enthusiastic 
teacher, he was 
instrumental in 




pplications are invited for the annual Louis 
Vogelpoel Travelling Scholarship for 2020. 
An amount of up to R20 000 towards the 
travel and accommodation costs of a local or interna-
tional congress will be offered annually by the Western 
Cape branch of the South African Heart Association in 
memory of one of South Africa’s outstanding cardiologists, 
Dr Louis Vogelpoel. 
Louis Vogelpoel was a pioneer of cardiology in South 
Africa who died in April 2005. He was one of the 
founding members of the Cardiac Clinic at Groote Schuur 
Hospital and the University of Cape Town. He had an 
exceptional career of more than 5 decades as a dis-
tinguished general physician, cardiologist and horticultural 
scientist. Dr Vogelpoel’s commitment to patient-care, 
teaching and personal education is remembered by his 
many students, colleagues and patients. Medical students, 
house offi cers, registrars and consultants benefi ted from 
exposure to his unique blend of clinical expertise, extensive 
knowledge, enthusiasm and gracious style. 
A gifted and enthusiastic teacher, he was instrumental in 
the training of generations of undergraduates by regular 
bedside tutorials. He served as an outstanding role model 
for postgraduates and many who have achieved pro-
minence nationally and internationally acknowledged his 
contribution to the development of their careers. 
All applications for the scholarship will be reviewed by the 
executive committee of the Western Cape branch of the 
South African Heart Association. Preference will be given 
to practitioners or researchers in the fi eld of cardiovascular 
medicine who are members of the South African Heart 
Association and are resident in the Western Cape.
Applications should include: (1) A brief synopsis of the 
work the applicant wishes to present at the congress; and 
(2) A brief letter of what the applicant hopes to gain by 
attending the relevant congress. The applicant should sub-
mit an abstract for presentation at the relevant national or 
international meeting. Should such an abstract not be 
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HEFSSA TRAVEL SCHOLARSHIP 
INTRODUCTION
The Executive Committee of the Heart Failure Society of South Africa (HeFSSA) has established 
the HeFSSA Travel Scholarship. As part of its contribution towards optimising patient care and 
to enhance and promote local heart failure expertise, HeFSSA supports such an award in South 
Africa. We hope that the information gained during this event and the possibility of sharing your 
experience and opening a dialogue with other specialists, will broaden your knowledge 
regarding new products and therapies in your fi eld of expertise. We also hope that this 
experience will help you to develop educational programmes at your medical institution and to 
share the acquired knowledge with your colleagues actively.
VALUE
Two travel grants are available annually. Each grant is valued at a maximum of R35 000 which 
may be used towards economy airfare, registration and accommodation. 
ELIGIBILITY
Candidates may be a medical practitioner in the public or private sector (i.e. a cardiologist, 
physician, internal medicine practitioner, Cardiology Fellow or similar) or researcher (basic 
scientist in heart failure). Applicants must be paid-up members of the SA Heart® Association 
and HeFSSA. The programme/course/conference needs to be internationally or locally 
accredited and focussed on promoting your knowledge of heart failure.
APPLICATION
Applications can be submitted to HeFSSA at info@hefssa.org. Please include your contact 
details and hospital affi liation, qualifi cation, private and or public practice, and if you are an RSA 
citizen (or permanent resident). Provide a motivation as to why the specifi c programme or 
course has been selected and include the programme of the conference (or URL). The HeFSSA 
offi ce will confi rm receipt by return email. Application for this award does not guarantee that 
the applicant will receive the award. No correspondence will be entertained after a decision is 
made. The applicant will be notifi ed of the outcome of the applications within 4 weeks of 
receipt.
PROCESS AND TERMS
The grant recipient needs to book, pay and then claim back (with proof documentation) from 
HeFSSA. Refund will be actioned within 24 hours. Twenty percent of the grant amount will be 
retained by HeFSSA (R7 000) and will be paid to the recipient as soon as CPD certifi cate and 
a meeting report is received.
Within one month of returning from the conference, the recipient must submit a substantial 
evaluation/review of the course content. This should refl ect on key lectures and late-breaking 
trials as well as other sessions attended, which will impact on the practice going forward. 
Include some photographs. The purpose of this report is to share knowledge gained that could 
impact on colleagues’ practices. The report should be included in the SA Heart® newsletter 
and/or the HeFSSA newsletter. 
HeFSSA strongly recommends that the recipient create the opportunity to give feedback 
through a lecture delivered at appropriate educational forums (please confi rm with HeFSSA 
when these take place).
Should the recipient not attend the conference, HeFSSA reserves the right to request 
repay-ment of any monies paid.
“ENHANCING HEART FAILURE MANAGEMENT IN SOUTH AFRICA”
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THE SOUTH AFRICAN HEART ASSOCIATION
RESEARCH SCHOLARSHIP
This scholarship is available to full and associate members of the SA Heart® Association living in South Africa. 
It is primarily intended to assist colleagues involved in much-needed research to enhance their research 
programmes.
REQUIREMENTS
■  Applicants need to be fully paid up members/associate members in good standing for at least one year.
■  Applications must include:
 ■ The applicant’s abbreviated CV
 ■ A breakdown of the anticipated expenses
 ■ Ethics approval
 ■ Full details of the research
 ■ The completed application form  - please request a fillable MS Word document from erika@saheart.org
 ■ Contact details of Head of Department or supervisor/mentor
RECOMMENDATIONS
■   Preference will be given to early and mid-career applicants (<5 years post-qualification as specialist and/or 
<5 years post-PhD qualification).
CONDITIONS
■   Applicants may only submit 1 application every second year. Preference is given to those who have not had 
previous scholarships awarded.
■   Awards are granted for one specific research project. Should that specific project be cancelled or the full 
amount allocated not be utilised for any reason, then the funds must revert to SA Heart®.
APPLICATIONS MUST BE EMAILED TO:
erika@saheart.org
THE SELECTION PANEL WILL REVIEW APPLICATIONS ANNUALLY AND THE CLOSING 
DATE IS 30 SEPTEMBER 2020.
One scholarship to a maximum amount of R65 000 will be awarded annually.
SA Heart® commits to inclusive excellence by advancing equity and diversity.
We particularly encourage applications from members of historically under 
represented racial/ethnic groups, women and individuals with disabilities.
